Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorValassi, Elena
dc.contributor.authorChaysavanh, Manichanh
dc.contributor.authorAmodru, Vincent
dc.contributor.authorGonzález Fernández, Pedro
dc.contributor.authorGAZTAMBIDE, SONIA
dc.contributor.authorYañez, Francisca
dc.date.accessioned2023-06-27T09:43:53Z
dc.date.available2023-06-27T09:43:53Z
dc.date.issued2023-06-05
dc.identifier.citationValassi E, Manichanh C, Amodru V, González Fernández P, Gaztambide S, Yañez F, et al. Gut microbial dysbiosis in patients with Cushing’s disease in long-term remission: Relationship with cardiometabolic risk. Front Endocrinol. 2023 Jun 5;14:1074757.
dc.identifier.issn1664-2392
dc.identifier.urihttps://hdl.handle.net/11351/9906
dc.descriptionCushing's disease; Cardiovascular risk; Gut microbiota
dc.description.abstractBackground: Patients with Cushing’s disease (CD) in remission maintain an increased cardiovascular risk. Impaired characteristics of gut microbiome (dysbiosis) have been associated with several cardiometabolic risk factors. Methods: Twenty-eight female non-diabetic patients with CD in remission with a mean ± SD) age of 51 ± 9 years, mean ( ± SD) BMI, 26 ± 4, median (IQR) duration of remission, 11(4) years and 24 gender-, age, BMI–matched controls were included. The V4 region of the bacterial 16S rDNA was PCR amplified and sequenced to analyse microbial alpha diversity (Chao 1 index, observed number of species, Shannon index) and beta diversity analysis through the Principal Coordinates Analysis (PCoA) of weighted and unweighted UniFrac distances. Inter-group difference in microbiome composition was analysed using MaAsLin2. Results: The Chao 1 index was lower in CD as compared with controls (Kruskal-Wallis test, q = 0.002), indicating lower microbial richness in the former. Beta diversity analysis showed that faecal samples from CS patients clustered together and separated from the controls (Adonis test, p<0.05). Collinsella, a genus form of the Actinobacteria phylum was present in CD patients only, whereas Sutterella, a genus from Proteobacteria phylum, was scarcely detectable/undetectable in CD patients as well as Lachnospira, a genus of the Lachnospiraceae family of the Firmicutes phylum. In CS, the Chao 1 index was associated with fibrinogen levels and inversely correlated with both triglyceride concentrations and the HOMA-IR index (p<0.05). Conclusions: Patients with CS in remission have gut microbial dysbiosis which may be one of the mechanisms whereby cardiometabolic dysfunctions persist after “cure”.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Endocrinology;14
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectIntestins - Microbiologia
dc.subjectSistema cardiovascular - Malalties - Factors de risc
dc.subject.meshDysbiosis
dc.subject.meshGastrointestinal Microbiome
dc.subject.meshCardiovascular Diseases
dc.titleGut microbial dysbiosis in patients with Cushing’s disease in long-term remission: Relationship with cardiometabolic risk
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fendo.2023.1074757
dc.subject.decsdisbacteriosis
dc.subject.decsmicrobiota intestinal
dc.subject.decsenfermedades cardiovasculares
dc.relation.publishversionhttps://doi.org/10.3389/fendo.2023.1074757
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Valassi E] Endocrinology and Nutrition Department, Germans Trias i Pujol Hospital and Research Institute, Badalona, Spain. School of Medicine, Universitat Internacional de Catalunya (UIC), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Unit 747, ISCIII, Barcelona, Spain. [Manichanh C, Yañez F] Grup de Recerca en Microbioma, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Amodru V] Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Unit 747, ISCIII, Barcelona, Spain. [González Fernández P] Endocrinology Department, Cruces University Hospital, Bilbao, Spain. Biocruces Bizkaia, UPVEHU, CIBERDEM, Endo-ERN, SpainCruces Hospital, Bilbao, Spain. [Gaztambide S] Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Unit 747, ISCIII, Barcelona, Spain. Endocrinology Department, Cruces University Hospital, Bilbao, Spain. Biocruces Bizkaia, UPVEHU, CIBERDEM, Endo-ERN, SpainCruces Hospital, Bilbao, Spain
dc.identifier.pmid37342265
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record